Post on 08-Jun-2020
COL David HammerJoint Project Manager Medical Countermeasure Systems
The Pennsylvania State University OTA Symposium
BUILDING THE CBR DIAGNOSTIC FAMILY OF SYSTEMS
UNCLASSIFIEDDistribution Statement A:
Approved for public release; distribution
is unlimited.
January 15-16, 2019
PROTECTING THE JOINT FORCE
20190115 PSU BriefUNCLASSIFIED 2
DEPARTMENT OF DEFENSE
20190115 PSU BriefUNCLASSIFIED 3
Chemical Biological Defense Program
JOINT PRODUCT LEAD (JPDL) DIAGNOSTICS (DX)JPdL Diagnostics Mission
• Develop, acquire, integrate, and field identification technologies and Food and Drug Administration (FDA)-cleared diagnostic systems for the Warfighter and the Nation to aid in the diagnosis, prevention, and treatment of the effects of exposure to chemical, biological, and radiological (CBR) threats.
20190115 PSU BriefUNCLASSIFIED 4
DOD ROLES OF CARE
Combat Zone
ROLE 1: FIRST RESPONDER
ROLE 2: FORWARD
RESUSCITATIVE CARE
Aircraft CarrierLHA/LHD
ROLE 3: THEATER
HOSPITALIZATION
Theater Hospital
Mobile Forward Surgical Team
Expeditionary Medical Support
Aircraft CarrierFleet Surgical TeamLHA/LHD
SubmarineSurface
Combatant ShipsLSD/LPD
LSD / LPD
Submarine
Medical Treatment
Facilities Hospitals
Joint Base
Medical Evac
Forward Support Medical Company
BattalionAid Station
Combat Support Hospital
Decontamination
Shock Trauma PlatoonMedical Battalion Surgical
Expeditionary Medical Support
Forward Surgical Team
Decontamination
Combat Medic/Lifesaver
CHEM or BIO Incident
ROLE 4: DEFINITIVE
CARE
Medical Evac Vehicle
Treat & Return to
DutyTreat,
Stabilize & Expedite
Treat & Specialized Evacuation
Quarantine
20190115 PSU BriefUNCLASSIFIED 5
BREADTH AND DEPTHNotional End State
• Breadth: Total menu of diagnostic capabilityo Full breadth of coverage = diagnostic capability for all possible CBR threats
• Depth: The lowest role of medical care where a diagnostic test is clinically and operationally suitable
Breadth
Depth
Role 3
Role 2
Role 1
Bio Chem Rad
Fielded capability
Capability in development
No capability
20190115 PSU BriefUNCLASSIFIED 6
FAMILY OF SYSTEMSFamily of Systems concept
• A suite of diagnostic instruments and assays capable of diagnosing the full breadth of threats at all necessary roles of care
o No single technology will be capable of diagnosing all CBR-related diseaseNucleic acid, protein, polysaccharide, enzyme activity, small moleculeQualitative, quantitativeClinical sample type considerations
o No single instrument will be suitable for use at every role of careSize and weightPower ThroughputComplexity
20190115 PSU BriefUNCLASSIFIED 7
NEXT GENERATION DIAGNOSTIC SYSTEM INCREMENT 1
8
NGDS INCREMENT 1Program Goals
• Improve Biological Warfare Agent (BWA) diagnostic and detection capability
o Support clinical diagnosis to inform patient treatment decisionso Support Force Health Protection decision makingo Augment CBRN situational awareness
• Reduce overall complexity of diagnostic tests• Integrate CBRN diagnostics with everyday medical practice• Encourage development of additional panels of military
significance
20190115 PSU BriefUNCLASSIFIED 9
NGDS INCREMENT 1 SYSTEM
• FilmArray 2.0 instrument• Loading station• Ruggedized GETAC laptop computer• Hardened reusable shipping case• DOD-funded BWA Warrior Panel• DOD-funded Sentinel Panel
20190115 PSU BriefUNCLASSIFIED 10
DOD-FUNDED FILMARRAY PANELS
Warrior Panel Sentinel Panel(FDA-cleared) (Environmental identification)
Bacterial targetsBacillus anthracisYersinia pestisFrancisella tularensisCoxiella burnetiiViral TargetsEbolavirus
Zaire ebolavirusSudan ebolavirusBundibugyo ebolavirusTai Forest ebolavirusReston ebolavirus
MarburgvirusMarburg virusRavn virus
Bacterial targetsBacillus anthracisBurkholderia spp.Burkholderia pseudomalleiCoxiella burnetiiFrancisella tularensisBrucella spp.Brucella melitensisRickettsia prowazekiiViral targetEbolavirus
Zaire ebolavirusSudan ebolavirusBundibugyo ebolavirusTai Forest ebolavirusReston ebolavirus
MarburgvirusMarburg virusRavn virus
Orthopox virusesVariola virusVenezuelan Equine Encephalitis virusWestern Equine Encephalitis virusEastern Equine Encephalitis virus
Toxin gene targetsClostridium botulinumRicin communisTraining targetsBacillus globigiiBacillus thuringiensisSaccharomyces cerevisiae
20190115 PSU BriefUNCLASSIFIED 11
WARRIOR PANELIntended Use StatementThe FilmArray NGDS Warrior Panel is a qualitative, multiplexed, nucleic acid-based in vitro diagnostic test intended for use with the FilmArray 2.0 system. The FilmArray NGDS Warrior Panel detects and identifies Bacillus anthracis, Yersinia pestis, Francisella tularensis, Coxiella burnetii, Ebola virus, and Marburg virus nucleic acids directly from human whole blood (EDTA). The FilmArray NGDS Warrior Panel is also intended to be used to test for Bacillus anthracis or Yersinia pestis nucleic acids in blood cultures that are determined to be positive either by an automated system, by turbidity, or by daily Gram stain even without turbidity, and is indicated to be performed with concomitant Gram stain performed on positive blood culture specimens as per normal laboratory procedure. In addition, the FilmArray NGDS Warrior Panel may also be used to detect and identify Yersinia pestis and Francisella tularensis nucleic acids directly from sputum specimens.
The FilmArray NGDS Warrior Panel is intended to test individuals with signs and symptoms of infection from biothreat agents and/or individuals who are at risk for exposure or may have been exposed to these agents.
The FilmArray NGDS Warrior Panel is indicated as an aid in the diagnosis of anthrax, plague, tularemia, Q fever, and the hemorrhagic fevers caused by Ebola and Marburg viruses, in response to a suspected or confirmed bioterrorism event or outbreaks. It is for diagnostic use in conjunction with other clinical, epidemiologic, and laboratory data, in accordance with the guidelines provided by the appropriate Department of Defense and public health authorities.
Results are for the presumptive identification of Bacillus anthracis, Yersinia pestis, Francisella tularensis, Coxiella burnetii, Ebola virus, and Marburg virus. The definitive identification of Bacillus anthracis, Yersinia pestis, Francisella tularensis, Coxiella burnetii, Ebola virus, and Marburg virus requires additional testing and confirmation procedures in consultation with the appropriate Department of Defense and public health authorities for whom reports may be necessary. Negative results do not preclude infection with these biothreat agents and should not be used as the sole basis for diagnosis, treatment, or other patient management decisions.
The FilmArray NGDS Warrior Panel is solely for use by United States Department of Defense laboratories, and laboratories designated by the Department of Defense.
20190115 PSU BriefUNCLASSIFIED 12
NEXT GENERATION DIAGNOSTIC SYSTEM 2
13
NGDS INCREMENT 2Program Goals
• Expand the breadth and depth of CBRN diagnostics o Breadth: Total menu of diseases (Diagnostics beyond Polymerase Chain
Reaction (PCR))o Depth: Moving the tests closer to the point-of-need when both
operationally and clinically supportable
• Integrate CBRN diagnostics with everyday medical practiceo Routine healthcare testing (e.g. clinical chemistries)o Endemic infectious disease
• Seek Interim Fielding Capabilities (IFC): Pre-Emergency Use Authorization
• Complementary to NGDS Increment 1 (FilmArray)
20190115 PSU BriefUNCLASSIFIED 14
NGDS INCREMENT 2 MATERIEL SOLUTIONS
• NGDS Increment 2 is exploring multiple materiel solutions to expand the breadth and depth of CBRN diagnostics
o Man Portable Diagnostic System (MPDS)Addresses BW diagnostic gaps at lower roles of care (Role 1-2)
o Chemical Diagnostic (ChemDx)- organophosphate nerve agents Improved suitability relative to currently fielded EQM Test-mate diagnosticAddresses diagnostic gaps at lower roles of care (Role 1-2)
20190115 PSU BriefUNCLASSIFIED 15
MAN PORTABLE DIAGNOSTIC SYSTEM
• U.S. Special Operations Command (USSOCOM)o Small-team users with limited reach back to supportive care
Austere environments, outside of fixed laboratory (carried in)24-72 hours from definitive medical careUnnecessary evacuation creates mission impactsResources limited to what the team has locally, but users are highly trained
• Requirementso FDA cleared for use by appropriately trained personnelo Portable: Less than 5 lbs., fits in a backpack (<300 in3)o Durable: Operable in a range of environmental conditionso Powered: Battery operable/rechargeable, 5 or more runs/charge desiredo Stable: Consumables stable at Room Temperatureo Simple: Clinical Laboratory Improvement Amendments (CLIA) waived or
equivalent o Timely: Actionable result returned in <70 minutes
20190115 PSU BriefUNCLASSIFIED 16
MAN PORTABLE DIAGNOSTIC SYSTEMPotential Solutions
• Funding two candidate deviceso Cepheid GeneXpert Omni, Biomeme Three9 Dx
• Diagnostic Panelso Panel 1: Malaria, Dengue, Chikungunya, Zika, Leptospirosis
o Inclusion of Leptospira dependent on performance in capillary blood
o Panel 2: Ebola, Marburg, Lassa, CCHF o Panel 3: Virus vs. Bacteria Differentiation, host-response testo Panel 4: Bacterial Biothreat; agents dependent on final requirements from the Joint Services
20190115 PSU BriefUNCLASSIFIED 17
CHEMDXA Chemical Intoxication In Vitro Diagnostic
A low-cost, portable, rapid diagnostic of chemical warfare agent exposure that is easy to use and operationally suitable for battlefield environments.• In Vitro Diagnostics (IVD) of clinically-relevant
acetylcholinesterase (AChE)-inhibitiono Effective pre- and post-symptomaticallyo Low-to-high exposures o Variety of cholinesterase inhibiting agentso FDA clearance by 4QFY21
• Improved suitability for farther forward than Role 3o Austere battlefield environmentso Simple operation (CLIA-waivable)
• Alleviate need for previously-recorded, patient-specific baseline
20190115 PSU BriefUNCLASSIFIED 18
TODAY’S CBR DIAGNOSTIC LANDSCAPE
Breadth
Depth
Role 3
Role 2
Role 1
Bio Chem Rad
Fielded capability
Capability in development
No capability
20190115 PSU BriefUNCLASSIFIED 19
FUTURE DIRECTIONS AND OPPORTUNITIES
• Simpler, Faster, Smallero Improved operation suitabilityo Reduced training, reduced logistics burden, improved lifecycle sustainment
• Genomic Sequencingo Targeted sequencingo Agnostic sequencing
• Wearable Technologieso Real-time monitoring of Soldiers health
• Host Based Marker Discovery and Validationo Diagnosis of disease syndromeso Earlier disease diagnosiso Better inform operational medical decision making
20190115 PSU BriefUNCLASSIFIED 20
The right technology,at the right time,in the right place and for the right cost.
Jason Opdyke, PhDJoint Product Lead (Acting), DiagnosticsMedical Countermeasure Systems
301-619-4434jason.a.opdyke.civ@mail.milwww.jpeocbd.osd.mil
21
BACKUP
22
BIOFIRE DIAGNOSTICS COMMERCIAL PANELS
Respiratory Panel
Blood Culture Identification
Gastrointestinal Disease Panel
Meningitis/Encephalitis Panel
(FDA Cleared) Panel (FDA Cleared) (FDA Cleared) (FDA Cleared)Viral TargetsAdenovirusCoronavirus HKU1Coronavirus NL63Coronavirus 229ECoronavirus OC43Human MetapneumovirusHuman Rhinovirus/EnterovirusInfluenza AInfluenza A/H1Influenza A/H3Influenza A/H1-2009Influenza B*
Parainfluenza Virus 1Parainfluenza Virus 2Parainfluenza Virus 3Parainfluenza Virus 4Respiratory Syncytial VirusBacterial targetsBordetella pertussis, Chlamydophila pneumoniaeMycoplasma pneumonia
Gram + Bacterial targetsEnterococcusListeria monocytogenesStaphylococcusStaphylococcus aureusStreptococcusStreptococcus agalactiaeStreptococcus pyogenesStreptococcus pneumoniae
Gram – Bacterial targetsAcinetobacter baumanniiHaemophilus influenzaeNeisseria meningitidisPseudomonas aeruginosaEnterobacteriaceaeEnterobacter cloacae complexEscherichia coliKlebsiella oxytocaKlebsiella pneumoniaeProteusSerratia marcescens
Fungal targetsCandida albicansCandida glabrataCandida kruseiCandida parapsilosisCandida tropicalis
Antibiotic Resistance targetsmecA – methicillin resistantvanA / vanB – vancomycin restitantKPC – carbapenem resistant
Bacterial targetsCampylobacter (jejuni, coli, and upsaliensis)Clostridium difficile (toxin A/B)Plesiomonas shigelloides Salmonella Yersinia enterocolitica Vibrio (parahaemolyticus, vulnificusand cholera)Diarrheagenic E. coli/ShigellaEnteroaggregative E. coli (EAEC)Enteropathogenic E. coli (EPEC)Enterotoxigenic E. coli (ETEC) lt/stShiga-like toxin-producing E. coli (STEC) stx1/stx2E. coli O157Shigella/Enteroinvasive E. coli (EIEC)
Viral targetsAdenovirus F40/41 Astrovirus Norovirus GI/GII Rotavirus A Sapovirus (I, II, IV and V)Parasitic targetsCryptosporidium Cyclospora cayetanensis Entamoeba histolytica Giardia lamblia
Bacterial targetsEscherichia coli K1Haemophilus influenzaeListeria monocytogenesNeisseria meningitidisStreptococcus agalactiaeStreptococcus pneumoniae
Viral targetsCytomegalovirus (CMV)EnterovirusEpstein-Barr virus (EBV)Herpes simplex virus 1 (HSV-1)Herpes simplex virus 2 (HSV-2)Human herpesvirus 6 (HHV-6)Human parechovirusVaricella zoster virus (VZV)
Fungal targetsCryptococcus gattiiCryptococcus neoformans
20190115 PSU BriefUNCLASSIFIED 23
CHALLENGES TO SUCCESS
• Limited understanding of Molecular Pathology of diseaseso What markers are predictive of disease? (agent or host)o When do markers appear during disease course?o Where do markers accumulate? (sample types)
• Technologyo Operational suitability: Commercial Off the Shelf (COTS) or DoD specifico When to “buy in” to a technology?
• Concept of Operations (CONOPS)o Understanding how a test can be used in a deployed environment to
improve patient outcomes and operational decision making
• Regulatoryo Maintaining regulatory compliance in unconventional use scenarios
20190115 PSU BriefUNCLASSIFIED 24